| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | RM; RACE; CBAS4; AMACRD |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human AMACR |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于AMACR(α-甲基酰基辅酶A消旋酶)抗体的3篇参考文献，按文献名称、作者和摘要内容概括整理：
---
1. **文献名称**：*α-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer*
**作者**：Jiang Z, Woda BA, Rock KL, et al.
**摘要**：该研究首次提出AMACR作为前列腺癌特异性生物标志物，通过免疫组化分析显示其在癌组织中高表达，而在正常或良性前列腺组织中表达缺失，提示AMACR抗体在病理诊断中的潜在价值。
---
2. **文献名称**：*Role of α-Methylacyl-CoA Racemase in the Differential Diagnosis of Prostate Cancer*
**作者**：Rubin MA, Zhou M, Dhanasekaran SM, et al.
**摘要**：研究验证了AMACR抗体在鉴别前列腺癌与良性组织中的高敏感性和特异性，结合基底细胞标记物(如p63)可提高病理诊断准确性，推动其成为临床常规检测指标。
---
3. **文献名称**：*AMACR Expression in Prostatic Adenocarcinoma and Hepatocellular Carcinoma: A Comparative Study*
**作者**：Zhou M, Chinnaiyan AM, Kleer CG, et al.
**摘要**：通过比较AMACR抗体在不同癌症中的表达，发现其在前列腺癌和肝细胞癌中均显著上调，但与其他肿瘤标志物(如HepPar1)联合使用可提升鉴别诊断的可靠性。
---
**备注**：以上文献均发表于2000年代初，为AMACR抗体的早期关键研究，推动了其在肿瘤病理学(尤其是前列腺癌)中的应用。如需具体年份或期刊信息，可进一步补充检索PubMed或Web of Science数据库。
Alpha-methylacyl-CoA racemase (AMACR), also known as P504S, is a mitochondrial and peroxisomal enzyme involved in the β-oxidation of branched-chain fatty acids and bile acid intermediates. Its role in lipid metabolism and association with cancer was first identified in the early 2000s. AMACR gained prominence as a biomarker when studies revealed its overexpression in prostate cancer cells compared to benign prostatic tissue. This discovery positioned AMACR antibodies as valuable tools in diagnostic pathology.
In clinical practice, AMACR immunohistochemical staining is widely used to distinguish prostate adenocarcinoma from benign mimics, particularly in small biopsy specimens. Its utility extends to confirming malignancy in ambiguous glandular proliferations. AMACR is often combined with basal cell markers (e.g., p63. 34βE12) to improve diagnostic accuracy. Beyond prostate cancer, AMACR expression has been observed in other malignancies, including colorectal carcinoma, renal cell carcinoma, and some hepatocellular carcinomas, though with variable specificity.
While highly sensitive for prostate cancer (positive in ~80-95% of cases), AMACR's limitations include occasional negativity in certain subtypes (e.g., foamy or pseudohyperplastic variants) and focal positivity in benign conditions like nephrogenic adenoma. Despite these caveats, AMACR remains a cornerstone in modern pathology workflows, exemplifying the translation of molecular discoveries into practical diagnostic applications.
×
